aTyr Pharma, Inc. (NASDAQ:LIFE) Expected to Post Earnings of -$0.44 Per Share

Brokerages expect aTyr Pharma, Inc. (NASDAQ:LIFEGet Rating) to post ($0.44) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for aTyr Pharma’s earnings. The lowest EPS estimate is ($0.48) and the highest is ($0.36). aTyr Pharma posted earnings per share of ($0.64) during the same quarter last year, which would suggest a positive year over year growth rate of 31.3%. The business is expected to announce its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that aTyr Pharma will report full-year earnings of ($1.78) per share for the current year, with EPS estimates ranging from ($1.93) to ($1.54). For the next year, analysts forecast that the business will post earnings of ($1.88) per share, with EPS estimates ranging from ($2.50) to ($1.15). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover aTyr Pharma.

aTyr Pharma (NASDAQ:LIFEGet Rating) last issued its quarterly earnings data on Monday, May 9th. The biotechnology company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.10). During the same period last year, the business posted ($0.51) EPS.

Several research firms recently weighed in on LIFE. Zacks Investment Research upgraded shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $4.00 price target for the company in a research report on Wednesday, May 11th. Piper Sandler reduced their price target on shares of aTyr Pharma from $19.00 to $11.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, StockNews.com downgraded shares of aTyr Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, April 19th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $14.86.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP grew its stake in aTyr Pharma by 1.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 226,712 shares of the biotechnology company’s stock valued at $1,694,000 after acquiring an additional 2,433 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of aTyr Pharma by 1.9% in the 3rd quarter. Renaissance Technologies LLC now owns 179,655 shares of the biotechnology company’s stock valued at $1,631,000 after buying an additional 3,400 shares during the period. Charles Schwab Investment Management Inc. purchased a new stake in shares of aTyr Pharma in the 4th quarter valued at approximately $75,000. Qube Research & Technologies Ltd purchased a new stake in shares of aTyr Pharma in the 4th quarter valued at approximately $87,000. Finally, Virtu Financial LLC purchased a new stake in shares of aTyr Pharma in the 1st quarter valued at approximately $70,000. 77.96% of the stock is owned by institutional investors.

Shares of LIFE remained flat at $$3.00 during mid-day trading on Friday. 79,316 shares of the company traded hands, compared to its average volume of 90,696. aTyr Pharma has a 52-week low of $2.89 and a 52-week high of $13.10. The firm’s fifty day simple moving average is $4.56 and its 200 day simple moving average is $6.04. The stock has a market cap of $84.18 million, a PE ratio of -1.66 and a beta of 1.54.

aTyr Pharma Company Profile (Get Rating)

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.

Featured Stories

Get a free copy of the Zacks research report on aTyr Pharma (LIFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for aTyr Pharma (NASDAQ:LIFE)

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.